A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers

Completed · Phase 1

Conditions studied: Her2 Amplified Solid Tumors, Metastatic Breast Cancer

In brief

This study is an open-label Phase 1 trial of MM-111.

Key facts

Study ID

NCT00911898

Run by

Merrimack Pharmaceuticals

People needed

20

Starts

2009-06-01

Expected to finish

2012-03-01

Last updated by the study team

2015-01-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have histologically or cytologically confirmed advanced cancer that is:
• HER2 amplified (IHC 2+ or greater) based on archived tumor evaluation
• Heregulin positive based on a study required fresh biopsy sample performed at screening and confirmed by central laboratory
• Patients must have blocks of archived formalin-fixed, paraffin-embedded tumor tissue available for sectioning and immunohistochemical staining
• Patient's cancer must have recurred or progressed following standard therapy, have not responded to standard therapy, or for which no standard therapy exists.
• Patients must be >= 18 years of age
• Patients or their legal representatives must be able to understand and sign an informed consent
• Patients may have measurable or non-measurable tumor(s)
• Patients should have ECOG Performance Score (PS) 0 or 1
• Patients must have adequate bone marrow reserves as evidenced by:
• Absolute neutrophil count (ANC) >= 1,500/uL and
• Platelet count >= 100,000/uL
• Hemoglobin >= 9 g/dL
• Patients must have tumor tissue amenable to biopsy
• Patients must be willing to undergo biopsy prior to treatment to MM-111

You may not qualify if…

• Patients for whom potentially curative antineoplastic therapy is available
• Patients who are pregnant or lactating
• Patients with an active infection or with an unexplained fever greater than 38.5 C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled)
• Patients with untreated and/or symptomatic primary or metastatic CNS malignancies (patients with CNS metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial
• Patients with known hypersensitivity to any of the components of MM-111 or who have had hypersensitivity reactions to fully human monoclonal antibodies (patients with a history of hypersensitivity to trastuzumab, a humanized antibody, are not excluded)
• Patients with known HIV, hepatitis B or C (if patients have previously been treated for C and have undetectable viral loads, they can be considered eligible for the trial)

Where it is running

• University of Southern California Norris Comprehensive Cancer Center — Los Angeles, California, United States
• Indiana University (IUPUI) — Indianapolis, Indiana, United States
• Fox Chase Center — Philadelphia, Pennsylvania, United States
• South Texas Accelerated Research Therapeutics — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.